Will crowdfunding and general solicitation spur orphan drug development for biotechs?

Will crowdfunding and general solicitation spur orphan drug development for biotechs?

Making equity crowdfunding available to all investors is also a priority of SEC Chair Mary Jo White this fall. [...]new opportunities await for early-stage and emerging growth biotechs to fuel their efforts in research and development (R&D) through a larger pool of biotech investors.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Formulary (Cleveland, Ohio) Ohio), 2013-10, Vol.48 (10), p.343
1. Verfasser: Loucks, David
Format: Artikel
Sprache:eng
Schlagworte:
Angel investors
Biotechnology industry
Clinical trials
Costs
Crowdfunding
Drugs
FDA approval
Finance
Government finance
Marketing
Orphan drugs
Pharmaceutical industry
Portfolio investments
Portfolio management
Prescription drugs
R&D
Rare diseases
Research & development
Tax credits
Venture capital
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Making equity crowdfunding available to all investors is also a priority of SEC Chair Mary Jo White this fall. [...]new opportunities await for early-stage and emerging growth biotechs to fuel their efforts in research and development (R&D) through a larger pool of biotech investors.
ISSN:1082-801X
1938-1166